Laboratory of synthetic vaccines
Laboratory develops artificial vaccines based on synthetic peptide fragments of various proteins. Work is aimed at fighting with neurodegenerative diseases, particularly Alzheimer's disease.
Researchers make antibodies to endogenous neuronal receptors to block the binding of amyloid-beta receptors. In the Laboratory such neuronal receptors asa nicotinic acetylcholine receptor, prion protein receptor, receptor for glycation end-product and neurotrophin receptor are under their investigation. Also in the Laboratory peptide drugs direct stimulating protective effects are being developed. Nowadays they have successfully managed to create a peptide RAGE-60-76 (fragment of the glycation end-product’s receptor), which shows a therapeutic effect after intranasal incertion to mice with olfactory bulbectomy (an excision of the olfactory bulb in mice leads to the development of symptoms of Alzheimer's disease).
Earlier Laboratory had created vaccines that are inactivated viral and bacterial diseases, such as foot and mouth disease, poliomyelitis, encephalitis, meningococcus, and others. In addition, researchers received antibodies to the tumor-associated proteins for the diagnosis of cancer.
Laboratory cooperates with IBCh’s laboratories, Institute of Cell Biophysics, the A.N. Belozersky Institute of Physico-Chemical Biology, with the Faculty of Biology at Moscow State University and the Institute of Higher Nervous Activity and Neurophysiology RAS, as well as with institutes in Poland, Czech Republic and other countries.
Laboratory of synthetic vaccines was founded in 2004 on the basis of synthetic vaccines Group (since 1987).
The theoretical and practical approach to creation of artificial vaccines on the basis of synthetic fragments of viral and bacterial proteins. Prediction and synthesis of immunoactive peptide fragments of endogenous proteins for induction of diagnostic and therapeutic antibodies.
- Creation of artificial vaccine against foot-and-mouth disease on the basis of synthetic fragments of VP1 viral protein.
- Induction of anti-meningitis protective immunity against A, B and C serogroups using the synthetic fragments of outer membrane proteins from Neisseria meningitides and the peptides conjugated with high-molecular capsule polysaccharides of the serogroup A meningococcus.
- Development of the peptide vaccine against tick-borne encephalitis on the basis of synthetic fragments of viral NS1 and E proteins
- Induction with synthetic peptides of polyclonal and monoclonal antibodies for diagnostics and therapy of prion diseases.
- Development of new approach to the immunotherapy of Alzheimer’s disease with the synthetic fragments of alpha 7 subunit of the acetylcholine receptor. Investigation of molecular mechanisms of cholinergic system action with the antibodies against synthetic fragments of alpha 7 subunit of the acetylcholine receptor.
- Induction of diagnostic antibodies against tumor associated proteins — nucleiphosmin and survivin, using synthetic peptides.
|Olga Volpina, D.Sc, professor||depart. firstname.lastname@example.org, |
|Tat'jana Volkova, Ph.D.||s. r. email@example.com, |
|Dmitri Koroev, Ph.D.||s. r. firstname.lastname@example.org, |
|Margarita Filatova, Ph.D.||s. r. email@example.com, |
|Anna Kamynina||r. firstname.lastname@example.org, |
|Galina Petrova||t. q. - lab. as.|
|Samson Balasanyants||pr. lab. as.|
|Ol'ga Chibiskova||j. r. f.|
Synthetic fragment of receptor for advanced glycation end products prevents memory loss and protects brain neurons in animals with experimentally induced Alzheimer’s disease. (2017-12-15)
It was established the relationship between ability of synthetic fragments of receptor for advanced glycation end products administrated intranasally as well as immunized to prevent memory loss in animals with experimentally induced Alzheimer’s disease and to prevent neuronal death and to decreased the amyloid-beta level in the brain. Using fluorescent labeled peptide, we revealed its penetration in the brain of mice and colocalization of peptide with amiloyd-beta plaques. It was shown that amyloid-beta can be one of the molecular target of active peptide. These findings provide a new approach for design of anti-Alzheimer’s disease therapy.
- (2018). Synthetic Fragment of Receptor for Advanced Glycation End Products Prevents Memory Loss and Protects Brain Neurons in Olfactory Bulbectomized Mice. J Alzheimers Dis 61 (3), 1061–1076
- (2017). A synthetic fragment 60–70 of the receptor for advanced glycation end products exhibits a therapeutic effect in an animal model of Alzheimer’s disease. Russ. J. Bioorganic Chem. 43 (2), 150–154